Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 20, Issue 14, pp. 3730-3741
PubMed
Published By
Print ISSN
Online ISSN
History
- Received December 20, 2013
- Revision received May 6, 2014
- Accepted May 8, 2014
- Published first May 16, 2014.
Article Versions
- Previous version (May 16, 2014 - 07:34).
- Previous version (June 30, 2014 - 07:23).
- You are viewing the most recent version of this article.
Copyright & Usage
©2014 American Association for Cancer Research.
Author Information
- Shiv K. Gupta1,
- Ann C. Mladek1,
- Brett L. Carlson1,
- Felix Boakye-Agyeman2,
- Katrina K. Bakken1,
- Sani H. Kizilbash1,
- Mark A. Schroeder1,
- Joel Reid2, and
- Jann N. Sarkaria1,*
- Authors' Affiliations: Departments of 1Radiation Oncology, and
- 2Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester Minnesota
- ↵*Corresponding Author:
Jann N. Sarkaria, Department of Radiation Oncology, Mayo Clinic, 200 First Street South West, Rochester, MN 55905. Phone: 507-284-8227/507-284-9025; Fax: 507-284-3906; E-mail: sarkaria.jann{at}mayo.edu
July 2014
Volume 20, Issue 14
Volume 20, Issue 14
Discordant In Vitro and In Vivo Chemopotentiating Effects of the PARP Inhibitor Veliparib in Temozolomide-Sensitive versus -Resistant Glioblastoma Multiforme Xenografts
Jump to section
Advertisement